Don't Miss Our New Year's Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
180 Life Sciences ( (ATNF) ) has issued an update.
At the 2024 Annual Meeting, 180 Life Sciences Corp. stockholders approved several key proposals, including the Third Amendment to the 2022 Omnibus Incentive Plan and the election of two Class II directors, Blair Jordan and Ryan Smith. The approval of new stock issuance proposals aligns with Nasdaq Listing Rules and enables conversion of Series B Convertible Preferred Stock into common stock, impacting the company’s capital structure and providing flexibility in managing outstanding warrants.
More about 180 Life Sciences
180 Life Sciences Corp. operates in the biotechnology sector, focusing on the development of therapies for inflammation, fibrosis, and pain. The company is engaged in advancing innovative treatment solutions to address unmet medical needs.
YTD Price Performance: -52.17%
Average Trading Volume: 2,319,891
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.84M
Learn more about ATNF stock on TipRanks’ Stock Analysis page.
